Heidi Cuthbert - Author on Grafa
All
bioAffinity revenue hits $6.2M as CyPath lung adoption surges 87%
bioAffinity Technologies (NASDAQ:BIAF) reported fiscal year 2025 results that underscore an aggressive transition from a broad laboratory service model to a specialized, high-growth diagnostic powerhouse focused on early-stage lung cancer detection.
Eupraxia Pharmaceuticals extends runway to 2028 on positive "RESOLVE" data
Eupraxia Pharmaceuticals (NASDAQ:EPRX) has secured a long-term financial runway, shifting focus toward pivotal data readouts for its lead gastrointestinal program following a successful fourth quarter and a transformative February financing.










